by Eddie Bishop | Sep 1, 2021 | EPO
In the present case the patentee wished to rely on documents dated after the filing date for their inventive step argument, stating that these documents in combination with data in the application as filed provided evidence of a synergistic effect between two...
by Carolyn Haywood | Feb 1, 2021 | US & International
Background The patent at issue in the present case was US7,772,209, claim 1 of which is shown below. Claim 1 A method for administering pemetrexed disodium to a patient in need thereof comprising administering an effective amount of folic acid and an effective amount...
by Eddie Bishop | Dec 1, 2020 | US & International
As a brief recap, claim 1 of Eli Lilly’s patent requires vitamin B12 + Pemetrexed disodium and claim 2 requires vitamin B12 + Pemetrexed disodium + folic binding protein. The potential infringer, Fresenius, used a composition including Pemetrexed tromethamine in...
by Alex Bajjon | Oct 1, 2020 | US & International
Paediatrics Regulation In Europe, Orphan Medicinal Products are medicinal products that are intended for the treatment of conditions that affect no more than 5 in 10,000 people in the EU. In order to incentivise the development of treatments for these rare conditions,...
by Carolyn Haywood | Aug 1, 2020 | US & International
Background Supplementary Protection Certificates (SPCs) are available under EU law to effectively compensate patent owners for some of the lost patent protection that inevitability occurs due to the time it takes to obtain marketing authorisation. Article 3 of the SPC...
Recent Comments